With promising interim phase 2 data in hand, Cybin believes psychedelic therapy will become a reality in the “not too distant future,” according to CEO Doug Drysdale. As recently as the 1990s, it would be difficult to imagine that a psychedelic drug would potentially be a clinical option for a mood disorder like depression. But…
Aiming to tame psychedelics’ wild side in pursuit of FDA approval
Doors of perception: Psychedelic renaissance or Pandora’s box? In one sense, psychedelics have always been divisive in mainstream Western culture. During their heyday in the 1960s, proponents lauded psychedelics’ virtues for psychological healing and exploration. Troubling reports also emerged — stories of bad trips, psychological breaks, and mostly apocryphal yet sensationalized reports of individuals leaping…